Head-to-head

Acarbose vs Canagliflozin

Two approved diabetes drugs cleared the same NIA mouse longevity bar with the same male-only pattern — the choice between them, taken off-label for aging, comes down to side-effect profile, not the mouse data.

Acarbose

Precose

FDA-approved

FDA-approved alpha-glucosidase inhibitor for diabetes, with a repeated, male-skewed median-lifespan extension in the NIA ITP mouse program — the same pattern later seen with canagliflozin. No human longevity trial exists; taking it off-label for aging means acting ahead of the evidence, not on it.

Full Acarbose evidence review

Canagliflozin

Invokana

FDA-approved

FDA-approved SGLT2 inhibitor with real cardiovascular and renal outcome trials (CANVAS, CREDENCE) — but the longevity claim rests entirely on a 14% median-lifespan extension in male-only NIA ITP mice; no human longevity trial exists, and the drug carries real risks (amputation, Fournier's gangrene, euglycemic DKA) that apply the same whether it's prescribed for diabetes or taken off-label for aging.

Full Canagliflozin evidence review

Side by side

	Acarbose	Canagliflozin
Marketed for	Type 2 diabetes (approved); explored for longevity via NIA ITP mouse data	Type 2 diabetes (approved); explored off-label for longevity on mouse ITP data
Evidence grade	FDA-approved	FDA-approved
Family	Metabolic / AMPK	Metabolic / AMPK
Key human source	Harrison 2014 NIA ITP, Aging Cell	Miller 2020 NIA ITP, JCI Insight

marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Our verdict

Both extended median lifespan in the NIA Interventions Testing Program, repeatably, and both showed the effect mostly or entirely in male mice — a genuine, unexplained puzzle, not a reason to prefer one over the other. Where they differ is the human safety record: acarbose's main issue is GI tolerability (gas, bloating), while canagliflozin carries real risks — amputation, Fournier's gangrene, euglycemic DKA — with no acarbose equivalent. Neither has a human longevity trial; both remain hypotheses borrowed from mice.

Acarbose fits if

You want the milder, GI-side-effect-only safety profile, and you can tolerate the digestive adjustment period.

Canagliflozin fits if

You have (or are managing) type 2 diabetes already and canagliflozin is a legitimate part of that regimen — using it off-label purely for the mouse longevity signal is a different, harder-to-justify decision given its more serious risk profile.